Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05260723 · ClinicalTrials.gov registry record · NA
RISE - Reduce Sitting Time Among Breast Cancer Survivors
A NA study, sponsored by University of California, San Diego.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT05260723: Completed NA study, sponsored by University of California, San Diego.
NCT05260723 is a NA study that has completed, run by University of California, San Diego. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05260723, a NA study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
This 3-month study will test whether a program to reduce sitting time, for breast cancer survivors experiencing some physical limitations, can improve their physical function and other important aspects of quality of life.
Primary Outcome
Percent of participants returning for the 3 month measures
Interventions
- BEHAVIORAL Behavioral: Sit Less
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2023-05-07 |
| Phase | NA |
What the finished NCT05260723 record still lists
NCT05260723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Behavioral: Sit Less is the first listed.
NCT05260723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05260723 about?
NCT05260723 is a clinical study titled "RISE - Reduce Sitting Time Among Breast Cancer Survivors". This 3-month study will test whether a program to reduce sitting time, for breast cancer survivors experiencing some physical limitations, can improve their physical function and other important aspects of quality of life.
What is the current status of trial NCT05260723?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2022-03-29. Estimated completion is 2023-05-07.
What interventions are being tested in trial NCT05260723?
The interventions under investigation include: Behavioral: Sit Less (BEHAVIORAL).
Who is sponsoring clinical trial NCT05260723?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05260723's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI